These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32346557)

  • 21. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
    Fisher M; Gore M
    Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New developments in treatment of ovarian carcinoma: focus on trabectedin.
    Cassier PA; Duret A; Trédan O; Carrabin N; Méeus P; Treilleux I; Guastalla JP; Ray-Coquard I
    Cancer Manag Res; 2010 Oct; 2():233-42. PubMed ID: 21188115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.
    Grenader T; Rosengarten O; Isacson R; Plotkin Y; Gabizon A
    World J Clin Oncol; 2012 Oct; 3(10):137-41. PubMed ID: 23198277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient.
    Colombo N
    EJC Suppl; 2014 Dec; 12(2):7-12. PubMed ID: 26759526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
    Marth C
    Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
    Colombo N; Hardy-Bessard AC; Ferrandina G; Marth C; Romero I
    Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):11-19. PubMed ID: 27797622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
    Colombo N
    Future Oncol; 2013 Dec; 9(12 Suppl):19-23. PubMed ID: 24195526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Xiu L; Cakana A; Parekh T; San-Miguel JF
    Cancer; 2016 Jul; 122(13):2050-6. PubMed ID: 27191689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer.
    Lorusso D; Ferrandina G; Lo Voi R; Fagotti A; Scambia G
    J Chemother; 2004 Nov; 16 Suppl 4():98-103. PubMed ID: 15688622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
    Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.
    Monk BJ; Kaye SB; Poveda A; Herzog TJ; Aracil M; Nieto A; Badri N; Parekh TV; Tanović A; Galmarini CM
    Gynecol Oncol; 2014 Jan; 132(1):176-80. PubMed ID: 24211400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience.
    Lee YJ; Kim YM; Kim HJ; Choi SW; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YT; Nam JH
    Obstet Gynecol Sci; 2017 Sep; 60(5):433-439. PubMed ID: 28989919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer.
    Pignata S; Lauraine EP; du Bois A; Pisano C
    Crit Rev Oncol Hematol; 2010 Jan; 73(1):23-30. PubMed ID: 19782576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer.
    Pisano C; Cecere SC; Di Napoli M; Cavaliere C; Tambaro R; Facchini G; Scaffa C; Losito S; Pizzolorusso A; Pignata S
    J Drug Deliv; 2013; 2013():898146. PubMed ID: 23577259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma.
    Rose PG; Radeva M; Michener CM; Link N; Adbul-Karim F
    Int J Gynecol Cancer; 2017 Jun; 27(5):907-911. PubMed ID: 28498259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer.
    Guerra Alía EM; Sempere Ortega C; Cortés Salgado A; Sanchez Martínez C; Galindo Álvarez J; Pérez Miez B
    Case Rep Oncol; 2019; 12(2):447-455. PubMed ID: 31275136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.
    Nicoletto MO; Baldoni A; Casarin A; Randon G; Nardin M; Baretta Z; Lardelli P; Nieto A; Alfaro V; Rigamonti C; Conte PF
    Tumori; 2015; 101(5):506-10. PubMed ID: 26108247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis.
    Lorusso D; Sabatucci I; Maltese G; Lepori S; Tripodi E; Bogani G; Raspagliesi F
    Tumori; 2019 Aug; 105(4):282-287. PubMed ID: 30917765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.